Literature DB >> 25771465

Seroprevalence of hepatitis viruses and risk factors in blood donors of Veracruz, Mexico.

Nayali Lopez-Balderas1, Elide Bravo, Mireya Camara, Pablo Hernandez-Romano.   

Abstract

INTRODUCTION: Hepatitis B and C are among the most important transfusion-transmitted infections and sources of liver diseases worldwide. In Veracruz, Mexico, liver diseases are important causes of mortality, and the prevalence reports of these viruses are scarce. This study sought to determine the prevalence of these infections in blood donors, in order to increase the safety of blood products in this region.
METHODOLOGY: A retrospective study was performed on blood donors who attended the Veracruz State Blood Transfusion Center from 2006 to 2010. All samples were screened for transfusion-transmitted infections. The prevalence rates of hepatitis B virus (HBV) and hepatitis C virus (HCV) were determined, and demographic data obtained from clinical records were used to evaluate risk factors.
RESULTS: A total of 56,377 donors were serologically screened; of them, 403 were seropositive for HCV (357 men and 46 women), and 61 were positive for HBsAg (52 men and 9 women). The overall prevalence rates were 0.72% (0.63%-0.76%) for HCV and 0.11% (0.08%-0.14%) for HBsAg. The risk factors for HBsAg positivity were being a cattleman and living in the Huasteca Baja region, whereas those for HCV were being a fisherman, living in the Papaloapan region, and having an elementary-level or lower education.
CONCLUSIONS: This is the first study to show that being a fisherman is a risk factor for HCV. The implementation of nucleic acid test technology will help to identify the real risks for transfusion-transmitted hepatitis C in Veracruz.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25771465     DOI: 10.3855/jidc.4812

Source DB:  PubMed          Journal:  J Infect Dev Ctries        ISSN: 1972-2680            Impact factor:   0.968


  3 in total

1.  Prevalent hepatitis B surface antigen among first-time blood donors in Gabon.

Authors:  Jean Marie Eko Mba; Cyrille Bisseye; Jophrette Mireille Ntsame Ndong; Landry Erik Mombo; Calixte Bengone; Guy Mouelet Migolet; Bertrand M'batchi; Heidi E Kosiorek; Richard J Butterfield; Lewis R Roberts; Mitesh J Borad; Bolni Marius Nagalo
Journal:  PLoS One       Date:  2018-04-13       Impact factor: 3.240

2.  Is topical or intravenous tranexamic acid preferred in total hip arthroplasty? A randomized, controlled, noninferiority clinical trial.

Authors:  Kai-di Zhou; Hong-Yi Wang; Yi Wang; Zhi-Hong Liu; Chuan He; Jian-Min Feng
Journal:  PLoS One       Date:  2018-10-02       Impact factor: 3.240

3.  Intravenous versus topical tranexamic acid in lumbar interbody fusion: A protocol of randomized controlled trial.

Authors:  Fei Song; Zhouhai Zheng
Journal:  Medicine (Baltimore)       Date:  2020-06-12       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.